# Thermo Fisher Scientific

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/thermo-fisher-scientific
Canonical HTML page: https://getyourbrief.com/entity/thermo-fisher-scientific

## Timeline

- **2026-02-26**: Novartis Settlement — Novartis reaches an agreement to resolve the estate's claims of unjust enrichment.
- **2023-08-01**: Thermo Fisher Settlement — The Lacks estate reaches the first major settlement with a biotech company over HeLa cells.
- **1951-10-04**: Death of Henrietta Lacks — Lacks passes away from cancer, unaware her cells have become the first immortal human cell line.
- **1951-02-01**: Cells Harvested — Henrietta Lacks' cervical cancer cells are harvested at Johns Hopkins without her consent.

## Recent coverage (5 stories, network-wide)

### Abbott's 42% Diagnostics Surge vs Thermo Fisher's Recovery: Which Wins?
2026-08-24 02:36:34 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For health system executives, clinical lab directors, and healthcare investors, this comparison is a real-world barometer of whether diversified diagnostic platforms or life sciences recovery will shape vendor and research spending. Abbott's 42% diagnostics jump to $3.09B, driven by Cologuard and Exact Sciences, points to durable non-invasive screening demand. Thermo Fisher's improving pharma and biotech activity signals a potential rebound in research tool budgets.
Full story: https://gethealthbrief.com/story/abbott-thermo-fisher-health-diagnostics-vs-recovery

### Nokia’s AI Cloud Revenue Rockets 105% to €446M, Orders Hit €2.8B in Q2
2026-07-24 02:53:28 · Sector: saas · Sentiment: Strongly positive · Impact: 7/10 · Sources: 2

Nokia’s Q2 2026 results crowned a new leader in the AI infrastructure boom: its AI & Cloud segment sales more than doubled to €446M, while a €2.8B order book points to sustained hypergrowth. Combined with Nasdaq’s 16% ARR rise in fintech, the day’s reports reinforce the recurring-revenue shift.
Full story: https://getsaasbrief.com/story/nokia-ai-cloud-revenue-105-percent-eur-446m

### Nasdaq Smashes Records with $1.5B Revenue as Q2 Earnings Show Broad Resurgence
2026-07-24 02:53:12 · Sector: finance · Sentiment: Strongly positive · Impact: 7/10 · Sources: 2

The July 23 earnings flood from Nasdaq, Nokia, Comcast, CEMEX, and Thermo Fisher revealed a broadening bull market. Nasdaq posted a record $1.5B revenue and $1.07 EPS, while AI cloud orders boomed and Peacock turned profitable, underscoring diverse sector strength.
Full story: https://getfinancebrief.com/story/nasdaq-15b-revenue-q2-2026-earnings-broad-growth

### Novartis Settles With Henrietta Lacks Estate Over Unauthorized HeLa Cell Use
2026-02-27 01:22:07 · Sector: legal · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Novartis has reached a settlement with the estate of Henrietta Lacks, addressing the decades-long commercial exploitation of her 'immortal' HeLa cells without consent. This agreement marks a significant legal precedent for the biotechnology industry, highlighting the shift toward accountability for biological material provenance in modern medicine.
Full story: https://getlegalbrief.com/story/novartis-settles-henrietta-lacks-hela-cells

### Seer Surpasses Q4 Earnings Estimates Amid Proteomics Market Expansion
2026-02-27 00:53:38 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Seer (NASDAQ: SEER) reported quarterly earnings that exceeded analyst expectations by $0.03 per share, signaling resilience in the life sciences tools sector. The results highlight growing adoption of the company's Proteograph Product Suite as researchers increasingly prioritize high-resolution proteomics in drug discovery.
Full story: https://getbiobrief.com/story/seer-nasdaq-seer-q4-earnings-beat-proteomics-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.